Cargando…
In vitro and in vivo drug disposition of cilengitide in animals and human
Cilengitide is very low permeable (1.0 nm/sec) stable cyclic pentapeptide containing an Arg‐Gly‐Asp motif responsible for selective binding to αvβ3 and αvβ5 integrins administered intravenously (i.v.). In vivo studies in the mouse and Cynomolgus monkeys showed the major component in plasma was uncha...
Autores principales: | Dolgos, Hugues, Freisleben, Achim, Wimmer, Elmar, Scheible, Holger, Krätzer, Friedrich, Yamagata, Tetsuo, Gallemann, Dieter, Fluck, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804314/ https://www.ncbi.nlm.nih.gov/pubmed/27069630 http://dx.doi.org/10.1002/prp2.217 |
Ejemplares similares
-
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016) -
A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide
por: Lüpfert, Christian, et al.
Publicado: (2018) -
Gene expression profiling of the anti-glioma effect of Cilengitide
por: Onishi, Manabu, et al.
Publicado: (2013) -
In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines
por: Lautenschlaeger, Tim, et al.
Publicado: (2013) -
Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients
por: Cedra, Susan, et al.
Publicado: (2017)